18 March 2013 | Regulatory | By BioSpectrum Bureau
Novartis eye care firm gets EU nod for Jetrea
Singapore: Alcon, the global leader in eye care and a division of Novartis, has received European Commission's approval for Jetrea intravitreal injection (ocriplasmin) in the EU for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.
"The approval of Jetrea by the European Commission is a major breakthrough for people with VMT and eye care professionals who, until now, have only had surgical options available to treat this debilitating eye disease. Now they can intervene early with a one-time injection of Jetrea," said Mr Stuart Raetzman, area president, Europe, Middle East and Africa, Alcon.
"Jetrea meets a genuine unmet patient need and demonstrates Alcon's commitment to bringing innovative eye care treatments to people in Europe and throughout the world," he added.